-
Product Insights
NewNet Present Value Model: Acurx Pharmaceuticals Inc’s Ibezapolstat
Empower your strategies with our Net Present Value Model: Acurx Pharmaceuticals Inc's Ibezapolstat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibezapolstat in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibezapolstat in Clostridioides difficile Infections (Clostridium difficile Associated Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibezapolstat in Clostridioides difficile Infections (Clostridium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2b LA in Essential Thrombocythemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2b LA in Essential Thrombocythemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2b LA in Essential Thrombocythemia Drug Details: Ropeginterferon alpha-2b...
-
Product Insights
Net Present Value Model: Acurx Pharmaceuticals Inc’s Ibezapolstat
Empower your strategies with our Net Present Value Model: Acurx Pharmaceuticals Inc's Ibezapolstat report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewStreptococcal Pneumonia – Drugs In Development, 2024
Empower your strategies with our Streptococcal Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate...
-
Product Insights
NewClostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024
Empower your strategies with our Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or "C. diff", a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk...
-
Product Insights
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024
Empower your strategies with our Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin...
-
Product Insights
NewNet Present Value Model: Arcellx Inc’s ACLX-002
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAT-076 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AAT-076 in Pain Drug Details:RMX-1001 is under development for the treatment of pain including cancer pain...
-
Product Insights
Therapeutic Drug Monitoring Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Therapeutic Drug Monitoring Pipeline Market Report Overview Therapeutic drug monitoring tests include reagents and test kits intended to measure different types of therapeutic drugs from samples ranging from serum/blood, urine, hair and sweat. The therapeutic drug monitoring pipeline market research report provides comprehensive information about the Therapeutic drug monitoring pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Immunosuppressant Therapeutic Drug Monitoring...